PKRA7 decreases subcutaneous and intracranial glioblastoma xenograft tumor growth.

<p>(<b>A</b>) D456MG cells were SC injected into nude mice, and control (n = 5) or PKRA7 (n = 5) treatment was commenced when tumors became visually detectable (14 days). Measurements were taken every 2–3 days. (<b>B</b>) Average tumor weight of control and PKRA7-treated mouse tumors after removal. (<b>C</b>) IHC staining using CD34 endothelial cell marker in D456MG SC tumors from mice treated with control or PKRA7. (<b>D</b>) Cumulative probability of vessel relative density as measured by CD34 staining. Vascular density of tumors decreased with PKRA7 treatment. (<b>E</b>) Representative pictures of H&E staining of sections from control and PKRA7-treated SC tumors (<b>F</b>) Quantification of necrotic regions from 5 slides of each tumor per treatment group, percentages of necrotic areas were measured by ImageJ (*p≤0.05). (<b>G</b>) 1×10⁴ D456MG cells were IC injected into nude mice and treatment started 7 days after tumor implantation. Mice in control (n = 8) or PKRA7 treatment (n = 9) group were sacrificed when they developed severe neurological phenotype indicative of tumor growth intracranially.